Related Experiment Videos
[Age-related macular degeneration]
Gisèle Soubrane1, Walid Michel Haddad, Gabriel Coscas
1Clinique ophtalmologique universitaire de Créteil, Université Paris XII, Créteil. gisele.soubrane@chicreteil.fr
Presse Medicale (Paris, France : 1983)
|September 20, 2002
Summary
Age-related macular degeneration (ARMD) is a leading cause of blindness in those over 55. While pathogenesis is unclear, current treatments focus on the exudative form, with new therapies under investigation.
Area of Science:
- Ophthalmology
- Gerontology
- Genetics
Context:
- Age-related macular degeneration (ARMD) is a primary cause of vision loss in individuals over 55, with prevalence increasing significantly with age.
- The exact pathogenesis of ARMD remains incompletely understood, implicating aging, genetic predispositions, and environmental factors.
Purpose:
- To summarize the epidemiological, pathogenic, and clinical aspects of ARMD.
- To review current and emerging therapeutic strategies for both atrophic and exudative forms of ARMD.
Summary:
- ARMD presents with precursors like drusen and retinal pigment epithelium (RPE) alterations, progressing to either atrophic (geographic atrophy) or exudative (neovascular) forms.
- The exudative form, characterized by choroidal neovascularization, is the main cause of ARMD-related blindness, leading to macular photoreceptor destruction.
- Current treatments for atrophic ARMD are palliative, while the exudative form can be managed with laser photocoagulation and photodynamic therapy, offering stabilization in many cases.
Impact:
- Highlights the significant public health burden of ARMD, particularly in aging populations.
- Underscores the need for further research into ARMD pathogenesis to develop more effective preventative and therapeutic interventions.
- Provides an overview of the therapeutic landscape, including established treatments and promising future directions such as anti-angiogenic therapies and regenerative medicine.